In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia?



Open Access Logo



There is an erratum to this paper published in Veterinary Evidence Vol 8, Issue 3 (2023):

PICO question

In dogs diagnosed with osteoarthritis (OA), how safe is treatment with bedinvetmab, when compared to a placebo and how effective in long-term reduction of the severity of the clinical signs associated with OA-related pain?


Clinical bottom line

Category of research


Number and type of study designs reviewed

Two papers were critically reviewed. One was a randomised, blinded, multi-arm laboratory safety study; the other a multi-center field trial consisting of a block-randomised, double blind, placebo-controlled phase, followed by a non-comparative, open-label case series study.

Strength of evidence


Outcomes reported

One study rated the reduction of the severity of clinical signs associated with OA pain using owner Canine Brief Pain Inventory (CBPI) ratings and non-validated veterinary clinical assessments (VCAs). Safety was addressed by evaluating adverse health effects (AHEs), concentration of antidrug antibodies (ADAs), and clinical pathology. Significant improvements in pain scores and VCAs were reported in this treatment study. The second safety-only study used clinical observation to evaluate AHEs. Both studies reported AHEs.


A single study suggests that treatment with bedinvetmab is effective. Two studies support the drug having few AHEs. Both studies have significant design limitations preventing the evaluation of bedinvetmab effectiveness. There is weak / inconclusive evidence for long-term efficacy and short-term safety of OA treatment with bedinvetmab. The decision to use bedinvetmab remains dependent on the judgement and experience of the clinician.

How to apply this evidence in practice

The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.

Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.


Barnett, A., van der Pols, J. & Dobson, A. (2005). Regression to the mean: what it is and how to deal with it. International Journal of Epidemiology. 34(1), 215–220. DOI:

Brown, D., Boston, R., Coyne, J. & Farrar, J. (2007). Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. American Journal of Veterinary Research. 68(6), 631–637. DOI:

Brown D., Boston R., Coyne J. & Farrar J. (2008). Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. Journal of the American Veterinary Medical Association. 233(8), 1278–1283. DOI:

Brown, D., Bell, M. & Rhodes, L. (2013). Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. American Journal of Veterinary Research. 74(12), 1467–1473. DOI:

Corral, M., Moyaert, H., Fernandes, T., Escalada, M., Tena, J., Walters, R. & Stegemann, M. (2021). A prospective, randomized, blinded, placebo–controlled multi–site clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia. 48(6), 943–955. DOI:

Donders, A., van der Heijden G., Stijnen, T. & Moons, K. (2006). Review: A gentle introduction to imputation of missing values. Journal of Clinical Epidemiology. 59(10), 1087–1091. DOI:

European Medicines Agency. (2021). Raylumis. [online]. Available from: [Accessed September 2022].

EMEA VICH Topic GL43. (2008). Guidance for Industry. Target Animal Safety for Veterinary Pharmaceutical Products. The European Agency for the Evaluation of Medicinal Products. EMEA/CVMP/VICH/393388/2006. [online]. Available from: [Accessed Nov 2021].

Enomoto, M. Mantyth, P., Murrell, J., Innes, J. & Lascelles, B. (2019). Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Veterinary Record. 184(1), 22–23. DOI:

Essner, A., Högberg, H., Zetterberg, L., Hellström, K., Sjöström, R., & Gustås, P. (2020). Investigating the Probability of Response Bias in Owner-Perceived Pain Assessment in Dogs with Osteoarthritis. Topics in Companion Animal Medicine. 39, 100407. DOI:

FDA. Tanezumab: FDA Efficacy Review. (2020). U.S. Food & Drug Administration. [online]. Available from: [Accessed September 2022].

Friedman, L., Furberg, C., DeMets, D., Reboussin, D. & Granger, C. (2015). Baseline assessment. In: L. Friedman, C. Furberg, D. DeMets, D. Reboussin & C. Granger eds., Fundamentals of Clinical Trials, 5th ed. Springer International Publishing Switzerland: Cham Springer, 201–213.

Gruen, M., Lascelles, B., Colleran, E., Gottlieb, A., Johnson, J., Lotsikas, P., Marcellin-Little, D. & Wright, B. (2022). 2022 AAHA Pain Management Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association. 58(2), 55–76. DOI:

Hochberg, M., Carrino, J., Schnitzer, T., Guermazi, A., Walsh, D., White, A., Nakajo, S., Fountaine, R., Hickman, A., Pixton, G., Viktrup, L., Brown, M., West, C. & Verburg, K. (2021). Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial. Arthritis & Rheumatology. 73(7), 1167–1177. DOI:

Hunt, J., Dean, R., Davis, G. & Murrell, J. (2015). An analysis of the relative frequencies of reported adverse events associated with NSAID administration in dogs and cats in the United Kingdom. The Veterinary Journal. 206(2), 183–190. DOI:

Krautmann, M., Walters, R., Cole, P., Tena, J., Bergeron, M., Messamore, J., Mwangi, D., Rai, S., Dominowski, P., Saad, K., Zhu, Y., Guillot, M., & Chouinard, L. (2021). Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. The Veterinary Journal. 276, 105733. DOI:

Lascelles B., Knazovicky, D., Case, B., Freire, M., Innes, J., Drew, A. & Gearing, D. (2015). A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Veterinary Research. 30(11), 101. DOI:

Monteiro-Steagall, B., Steagall, P. & Lascelles, B. (2013). Systematic review of Nonsteroidal Anti-Inflammatory Drug-Induced Adverse Effects in Dogs. Journal of Veterinary Internal Medicine. 27(5), 1011–1019. DOI:

Neogi, T., Hunter, D., Churchill, M., Shirinsky, I., White, A., Guermazi, A., Omata, M., Fountaine, R., Pixton, G., Viktrup, L., Brown, M., West, C., & Verburg, K. (2022). Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Research & Therapy. 24(1), 78. DOI:

Schnitzer, T., Ekman, E., Spierings, E., Greenberg, H., Smith, M., Brown, M., West, C., & Verburg, K. (2015). Efficacy and safety of tanezumab monotherapy or combined with non–steroidal anti–inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the Rheumatic Diseases. 74(6), 1202–1211. DOI:

Webster, R., Anderson G. & Gearing, D. (2014). Canine Brief Pain Inventory scores for dogs with osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor. American Journal of Veterinary Research. 75(6), 532–535. DOI:

Vol. 8 No. 1 (2023): The first issue of 2023

Section: Knowledge Summaries

Categories :  Small Animal  /  Dogs  /  Cats  /  Rabbits  /  Production Animal  /  Cattle  /  Sheep  /  Pig  /  Equine  /  Exotics  /